Adicet Bio, Inc.(ACET),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACET Adicet Bio, Inc.

Market Closed 12-12 16:00:00 EST

0.4987

-0.0181

-3.50%

盘后0.5133

+0.0146+2.93%

19:54 EST

High0.5257	Low0.4900	Vol3.89M
Open0.5100	D1 Closing0.5168	Amplitude6.91%
Mkt Cap76.43M	Tradable Cap65.83M	Total Shares153.26M
T/O1.97M	T/O Rate2.95%	Tradable Shares132.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACET","market":"US","secType":"STK","nameCN":"Adicet Bio, Inc.","latestPrice":0.4987,"timestamp":1765573200000,"preClose":0.5168,"halted":0,"volume":3889326,"hourTrading":{"tag":"盘后","latestPrice":0.5133,"preClose":0.4987,"latestTime":"19:54 EST","volume":13854,"amount":7059.2326,"timestamp":1765587256444},"delay":0,"floatShares":132000000,"shares":153255581,"eps":-1.261062,"marketStatus":"Market Closed","change":-0.0181,"latestTime":"12-12 16:00:00 EST","open":0.51,"high":0.525699,"low":0.49,"amount":1965551.5587212401,"amplitude":0.069077,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.261062,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1516942800000,"exchange":"NASDAQ","adjPreClose":0.5168,"preHourTrading":{"tag":"盘前","latestPrice":0.522,"preClose":0.5168,"latestTime":"09:26 EST","volume":9615,"amount":4993.9358114999995,"timestamp":1765549607557},"postHourTrading":{"tag":"盘后","latestPrice":0.5133,"preClose":0.4987,"latestTime":"19:54 EST","volume":13854,"amount":7059.2326,"timestamp":1765587256444},"volumeRatio":1.3072821580064105,"impliedVol":1.734,"impliedVolPercentile":0.472},"requestUrl":"/m/hq/s/ACET","defaultTab":"news","newsList":[{"id":"2587732870","title":"Adicet Bio Grants Inducement Stock Options to New Hire","url":"https://stock-news.laohu8.com/highlight/detail?id=2587732870","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587732870?lang=en_us&edition=fundamental","pubTime":"2025-11-29 03:23","pubTimestamp":1764357792,"startTime":"0","endTime":"0","summary":"Adicet Bio Inc. has granted a new hire non-qualified stock option award to one individual who joined the company in November 2025. The award consists of options to purchase 20,600 shares of Adicet's common stock at an exercise price of $0.65 per share, which was the closing price on November 28, 2025. One-fourth of the options will vest on the one-year anniversary of the employee's start date, with the remaining options vesting in thirty-six equal monthly installments, resulting in full vesting on the fourth anniversary of the start date, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via Business Wire  on November 28, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL10XCBF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2587732876","title":"Adicet Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2587732876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587732876?lang=en_us&edition=fundamental","pubTime":"2025-11-29 03:23","pubTimestamp":1764357780,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nTUA41F1DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2581000006","title":"Adicet Bio Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000006","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000006?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:48","pubTimestamp":1762519680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACET/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 07:48 ET (12:48 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACET"],"gpt_icon":0},{"id":"2581088134","title":"Adicet Bio Q3 EPS $(0.29) Beats $(0.30) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581088134","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581088134?lang=en_us&edition=fundamental","pubTime":"2025-11-06 06:09","pubTimestamp":1762380567,"startTime":"0","endTime":"0","summary":"Adicet Bio Q3 EPS $(0.29) Beats $(0.30) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48672433/adicet-bio-q3-eps-0-29-beats-0-30-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Adicet Bio Q3 EPS $(0.29) Beats $(0.30) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2581403709","title":"Adicet Bio Reports Positive Preliminary Phase 1 Data and Extends Cash Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581403709","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581403709?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:04","pubTimestamp":1762376651,"startTime":"0","endTime":"0","summary":"Adicet Bio Inc. announced its third quarter 2025 financial results and provided business updates. The company reported raising $74.8 million in net proceeds through an underwritten registered direct offering of equity securities in October 2025, extending its projected cash runway into the second half of 2027. Adicet Bio highlighted positive preliminary safety and efficacy data from its Phase 1 clinical trial of ADI-001 in patients with lupus nephritis  and systemic lupus erythematosus . As of the August 31, 2025 data cut-off, results showed rapid and sustained reductions in the Systemic Lupus Erythematosus Disease Activity Index  score and Physician's Global Assessment , improved renal function, and a favorable safety and tolerability profile. The company plans to request a meeting with the U.S. Food and Drug Administration  in the first quarter of 2026 to discuss the design of a potentially pivotal ADI-001 trial, with initiation targeted for the second quarter of 2026. Adicet Bio is ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL90yMPn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACET"],"gpt_icon":0},{"id":"2581272096","title":"Gene therapy firm MaxCyte misses Q3 revenue estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581272096","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581272096?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:13","pubTimestamp":1762348403,"startTime":"0","endTime":"0","summary":"Gene therapy firm MaxCyte misses Q3 revenue estimatesOverviewMaxCyte Q3 total revenue of $6.8 mln missed analyst expectationsCore business revenue declined 21% yr/yr to $6.4 mlnCompany maintains $158 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0PO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","MXCT","ACET","BK4139","BK4121"],"gpt_icon":0},{"id":"2580148134","title":"BRIEF-Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580148134","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580148134?lang=en_us&edition=fundamental","pubTime":"2025-11-01 05:52","pubTimestamp":1761947568,"startTime":"0","endTime":"0","summary":"BRIEF-Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Oct 31 (Reuters) - Adicet Bio Inc ACET.O:ADICET BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nBw7fckt5aFurther company coverage: ACET.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nTUA6GWFMR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACET"],"gpt_icon":0},{"id":"2580419980","title":"Adicet Bio Grants Stock Options to New Hires Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2580419980","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580419980?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:59","pubTimestamp":1761944352,"startTime":"0","endTime":"0","summary":"Adicet Bio Inc. has granted non-qualified stock options to five new hires in October 2025, totaling 97,200 shares of common stock at an exercise price of $0.75 per share, which was the closing price on October 31, 2025. For each employee, one-fourth of the option shares will vest on the first anniversary of their start date, with the remaining shares vesting in equal monthly installments over the following three years, fully vesting after four years, contingent upon continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via Business Wire  on October 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL1g9ntX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACET"],"gpt_icon":0},{"id":"2579816465","title":"Adicet Bio Inc  expected to post a loss of 29 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2579816465","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579816465?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:26","pubTimestamp":1761909965,"startTime":"0","endTime":"0","summary":"Adicet Bio Inc  expected to post a loss of29cents a share - Earnings Preview Adicet Bio Inc ACET.OQ ACET.O is expected to  show no change in quarterly revenue when it reports  results on November 4 (e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC10G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2576031341","title":"Canaccord Genuity Remains a Buy on Adicet Bio (ACET)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576031341","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576031341?lang=en_us&edition=fundamental","pubTime":"2025-10-17 18:55","pubTimestamp":1760698543,"startTime":"0","endTime":"0","summary":"In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Adicet Bio, with a price target of $8.00. The company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-adicet-bio-acet-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-adicet-bio-acet-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACET"],"gpt_icon":0},{"id":"2575710822","title":"Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Adi-001 in Treatment-Refractory Rheumatoid Arthritis (Ra)","url":"https://stock-news.laohu8.com/highlight/detail?id=2575710822","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575710822?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:00","pubTimestamp":1760612401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA23H5Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2575710355","title":"Adicet Bio Inc - Preliminary Data From Phase 1 Trial Expected in 2H/2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2575710355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575710355?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:00","pubTimestamp":1760612401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA23H5Y1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2573692555","title":"Adicet Bio Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2573692555","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573692555?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:39","pubTimestamp":1759927140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACET/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 08, 2025 08:39 ET (12:39 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2573799372","title":"Guggenheim Sticks to Their Buy Rating for Adicet Bio (ACET)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573799372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573799372?lang=en_us&edition=fundamental","pubTime":"2025-10-08 04:05","pubTimestamp":1759867517,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Yatin Suneja maintained a Buy rating on Adicet Bio today and set a price target of $8.00. The company’s shares closed today at $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-adicet-bio-acet-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-adicet-bio-acet-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACET"],"gpt_icon":0},{"id":"2573935319","title":"Adicet Bio Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2573935319","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573935319?lang=en_us&edition=fundamental","pubTime":"2025-10-08 04:02","pubTimestamp":1759867336,"startTime":"0","endTime":"0","summary":"**Adicet Bio Receives Nasdaq Extension to Regain Compliance with Listing Requirements** Adicet Bio Inc. announced that it has received a notice from Nasdaq granting the company an additional 180-day extension, until April 6, 2026, to regain compliance with the minimum $1.00 per share bid price requirement for continued listing. As a result, Adicet's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 9, 2025. The company is considering options, including a possible reverse stock split, to address the deficiency. If Adicet does not meet the bid price requirement within the extension period, its shares may be subject to delisting, though the company would have the right to appeal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL8dh3tM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACET"],"gpt_icon":0},{"id":"2573951277","title":"Adicet Bio Announces $80 Million Registered Direct Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2573951277","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573951277?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:01","pubTimestamp":1759834875,"startTime":"0","endTime":"0","summary":"Adicet Bio, Inc. , a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has announced the pricing of an $80 million registered direct offering. The offering consists of 70,001,000 shares of common stock at $1.00 per share and pre-funded warrants to purchase 10,000,000 shares at $0.9999 per warrant. All securities in the offering are being sold by Adicet. Jefferies and Guggenheim Securities are serving as joint book-running managers, with Truist Securities also acting as a joint bookrunner. Wedbush PacGrow and H.C. Wainwright & Co. are lead managers. The offering is expected to close subject to customary conditions. Proceeds will support Adicet's ongoing research and development efforts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL8BsdJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACET"],"gpt_icon":0},{"id":"2573495125","title":"Adicet Bio, Inc. Announces $80 Million Registered Direct Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2573495125","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573495125?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:01","pubTimestamp":1759834860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUA7QKYHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2573515369","title":"Adicet Bio Announces Positive Phase 1 Results for ADI-001 in Lupus Nephritis and SLE, Plans Pivotal Phase 2 Trial in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2573515369","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573515369?lang=en_us&edition=fundamental","pubTime":"2025-10-07 18:45","pubTimestamp":1759833918,"startTime":"0","endTime":"0","summary":"Adicet Bio Inc.  has announced positive preliminary data from its ongoing Phase 1 clinical trial evaluating ADI-001, an allogeneic gamma delta T cell therapy, in patients with lupus nephritis  and systemic lupus erythematosus . As of the August 31, 2025 data cut-off, all seven evaluable patients demonstrated rapid and sustained reductions in the Systemic Lupus Erythematosus Disease Activity Index  score and Physician's Global Assessment . Among the five LN patients, three achieved complete renal responses and DORIS remissions, while two showed partial renal responses, with all responses ongoing. The therapy was generally well tolerated, with no cases of Immune Effector Cell-Associated Neurotoxicity Syndrome  or Grade 2 or higher Cytokine Release Syndrome  observed. All patients were able to discontinue immunosuppressants and reduce corticosteroid use to physiological levels. Adicet Bio plans to meet with the U.S. Food and Drug Administration  in the first quarter of 2026 to discuss piv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL1bPnDb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2573951308","title":"Adicet Bio Inc - Adi-001 Well Tolerated With No Icans Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2573951308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573951308?lang=en_us&edition=fundamental","pubTime":"2025-10-07 18:45","pubTimestamp":1759833912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VN2TF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACET","BK4139"],"gpt_icon":0},{"id":"2573951306","title":"Adicet Bio Announces Positive Preliminary Data From Adi-001 Phase 1 Study in Patients With Lupus Nephritis (Ln) and Systemic Lupus Erythematosus (Sle)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573951306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573951306?lang=en_us&edition=fundamental","pubTime":"2025-10-07 18:45","pubTimestamp":1759833912,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VN2TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACET","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.restorbio.com","stockEarnings":[{"period":"1week","weight":-0.0665},{"period":"1month","weight":-0.2736},{"period":"3month","weight":-0.3845},{"period":"6month","weight":-0.3353},{"period":"1year","weight":-0.4882},{"period":"ytd","weight":-0.4816}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"resTORbio, Inc., a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to treat neurodegenerative diseases. resTORbio, Inc. has collaboration with TrialSpark to investigate RTB-101 for COVID-19 on the Project Covalence platform. resTORbio, Inc. was founded in 2016 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.011256},{"month":2,"riseRate":0.625,"avgChangeRate":0.014668},{"month":3,"riseRate":0.125,"avgChangeRate":-0.127363},{"month":4,"riseRate":0.5,"avgChangeRate":0.010766},{"month":5,"riseRate":0.375,"avgChangeRate":0.005307},{"month":6,"riseRate":0.25,"avgChangeRate":-0.066348},{"month":7,"riseRate":0.875,"avgChangeRate":0.156675},{"month":8,"riseRate":0.25,"avgChangeRate":-0.087324},{"month":9,"riseRate":0.375,"avgChangeRate":-0.03957},{"month":10,"riseRate":0.25,"avgChangeRate":-0.064136},{"month":11,"riseRate":0.5,"avgChangeRate":-0.065344},{"month":12,"riseRate":0.5,"avgChangeRate":0.04989}],"exchange":"NASDAQ","name":"Adicet Bio, Inc.","nameEN":"Adicet Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adicet Bio, Inc.(ACET),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adicet Bio, Inc.(ACET) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adicet Bio, Inc.,ACET,Adicet Bio, Inc.股票,Adicet Bio, Inc.股票老虎,Adicet Bio, Inc.股票老虎国际,Adicet Bio, Inc.行情,Adicet Bio, Inc.股票行情,Adicet Bio, Inc.股价,Adicet Bio, Inc.股市,Adicet Bio, Inc.股票价格,Adicet Bio, Inc.股票交易,Adicet Bio, Inc.股票购买,Adicet Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adicet Bio, Inc.(ACET),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adicet Bio, Inc.(ACET) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction